Treatment with ApoCell consists of retrieving a blood sample from the patient, treating it at the cell level in order to generate a homogenous apoptotic process, and re-infusing it to the patient. Enlivex's patented process for ex-vivo manipulation of the cells produces a stable, high cell dose of early apoptotic cells, with a very low rate of necrotic cells. Treatment with ApoCell is indicated for the acute phase of auto-immune conditions –such as acute GvHD and acute solid organ transplant rejection, or to induce remission in other autoimmune and inflammatory diseases such as Crohn’s disease. By using fully mature cells as a source to induce apoptosis, ApoCell's unique treatment modality has a very high safety profile, with no risk of differentiation into malignant cells. In addition, it avoids the cell expansion and growth process, as mature cells are theoretically unlimited in number.